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Available online 1 July 2016Considering the rising incidence of allergic asthma, the symptomatic treatments that are currently applied in
most cases are less than ideal. Speciﬁc immunotherapy is currently the only treatment that is able to change
the course of the disease, but suffers from a long treatment duration. A gene based immunization that elicits
the targeting of allergens towards dendritic cells in a steady-state environment might have the potential to
amend these difﬁculties. Here we used a replication deﬁcient adenovirus to induce the mucosal expression of
OVA coupled to a single-chain antibody against DEC-205. A single intranasal vaccination was sufﬁcient to miti-
gate an OVA-dependent asthmatic phenotype in a murine model. Invasive airway measurements demonstrated
improved lung function after Ad-Dec-OVA treatment, which was in line with a marked reduction of goblet cell
hyperplasia and lung eosinophilia. Furthermore OVA-speciﬁc IgE titers and production of type 2 cytokines
were signiﬁcantly reduced. Together, the here presented data demonstrate the feasibility of mucosal expression
of DEC-targeted allergens as a treatment of allergic asthma.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Mucosa1. Introduction
Asthma is one of the major issues of public health in industrialized
countries with an estimated 300 million affected people worldwide
and annual costs (both direct and indirect) of 18 billion in the USA
alone [1]. Symptomatically, asthma manifests in airway hyper respon-
siveness (AHR) towards unspeciﬁc stimuli, airway remodeling, and ep-
isodes of wheezing and airway obstruction. Asthma can be divided into
multiple endotypes with diverse etiologies, leading to the view that
asthma is rather a syndrome than a single disease [2]. Nevertheless,
most cases of asthma, especially during childhood, are attributed toﬂuid); IL, Interleukin; IFNγ,
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. This is an open access article underallergic reactions [3] towards harmless airborne allergens. This aller-
gy-dependent form of asthma is associated in about 90% of cases with
a TH2 polarization of the antigen-speciﬁc T-cell response, allergen-spe-
ciﬁc IgE production and inﬁltration of eosinophilic granulocytes into
the lung after inhalation of the allergen [4]. The standard therapy of
asthma consists of glucocorticoids andβ-adrenergic agonists, which un-
fortunately is a purely symptomatic treatment and ineffective in about
5–10% of patients [5]. Additionally, allergies in general are treated by
speciﬁc immunotherapy (SIT). This treatment consists of increasing
doses of the causative allergen given subcutaneously (SCIT) or
sublingually (SLIT) [6]. The exact mechanism of SIT is not fully elucidat-
ed yet andmight vary for different regimens. However, the induction of
regulatory T-cells and protective IgG antibodies that block IgE-mediated
activation of effector cells are likely to be involved. Although the safety
proﬁle as well as the efﬁcacy of SLIT and SCIT were demonstrated in re-
cent reviews [7,8], themajor drawbacks of these therapies are the long-
treatment-schedule with around 3–5 years and that it is not effective in
all allergic individuals. Attempts to reduce IgE mediated side effects of
SIT by the use of recombinant mosaic proteins, which lack most of the
conformational IgE-epitopes, have led to promising results for some
major allergens. However, these mosaic proteins require speciﬁc [9],
and occasionally extensive [10], molecular adaption for each allergen.
Another possible improvement to SIT might be the intralymphaticthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Treatment groups.
Group Number of animals (no. of ind. experiments)
Naïve 15 (3 exp.)
Asthma-Control 16 (3 exp.)
Ad-Dec-OVA 17 (3 exp.)
Ad-GL117-OVA 6 (1 exp.)
Ad-GFP 5 (1 exp.)
15A. Maaske et al. / Journal of Controlled Release 237 (2016) 14–22injection ofMHCII targeted fusion peptides, which leads to an enhanced
efﬁciency of peptide-presentation and a reduced binding by effector
cells. Thereby the number of injections as well as the antigen dose can
be reduced [11]. Besides reﬁnement of existing forms of therapy, vari-
ous newer routes for asthma treatment have been pursued. As TH1
cells and TH2 cells are reciprocally regulated, a multitude of studies en-
visaged the induction of TH1 based immune responses in order to re-
strict the TH2 responses towards allergens [12,13]. Adenoviral vector
immunization has been used to induce the intra-mucosal production
of the TH1 cytokine IFNγ [14] or the upstream acting IL-18 [15] and IL-
28A [16], which robustly reduced the secretion of TH2 cytokines after
stimulation with a model antigen. Furthermore, these treatments re-
duced asthmatic responses shortly after immunization, even after the
asthmatic phenotype was fully established. Based on the results of
these studies, it might be up to debate whether this effect is based
only on a transient suppression of TH2 cells, or whether there is also a
longterm effect on antigen-speciﬁc T-cells. However, even a shift of
the antigen-speciﬁc immune response towards TH1 does not prevent in-
ﬂammation [17] but might even lead to aggravation [18]. The notion
that TH1 polarization might be as detrimental as TH2 polarization was
supported by a recent report, showing high levels of IFNγ in severe
cases of asthma, as well as in murine asthma models [19].
As major contributors to the decision between immunity and toler-
ance, DCs are in the focus of various immune interventions [20,21], not
only regarding allergic responses. Direct targeting of antigens to surface
receptors expressed by DCs, such as Mannose Receptor, DEC-205, DC-
SIGN and Clec9a, leads to a speciﬁcally increased uptake, processing
and presentation of the antigen by DCs [22]. Especially for DEC-205
this targeting alone does not induce complete maturation or activation
of the DCs, making additional adjuvants necessary for the induction of
immunity. In contrast, in the absence of adjuvants this partial matura-
tion of DCs has led to tolerance induction, as was mainly shown in pro-
tein based approaches, for example as treatments for EAE or contact
dermatitis [23–26]. The exact mechanism of this tolerizing effect has
not been fully elucidated yet. However the induction of anergy in effec-
tor cells [25], induction of Tregs [26] and the induction of protective an-
tibodies [27] have been shown in different studies. The potential of
adenoviral vector based DEC-205 targeting approaches for the treat-
ment of allergic asthma has not been elucidated yet. Nonetheless, utiliz-
ing a viral vector with the capacity for transduction of the airway
mucosa provides considerable advantages in this regard.
Mucosal surfaces in general are in constant contact to foreign anti-
gens, most of which are innocuous, thus the mucosa has to be apt for
tolerance induction in order to prevent widespread immune pathology
[28,29]. Furthermore a treatment locally applied to the airway mucosa
would not only inﬂuence migratory cells, but would also shape the phe-
notype of tissue resident cells. In order to prevent anaphylactic reactions
induced by a targeted antigen, dose peaks are to be avoided. However,
frequent intratracheal low-dose application of a protein based treatment
would be difﬁcult, in contrast to a single dose, gene based immunization.
Additionally, for practical application gene based vaccinations beneﬁt
from a greater ﬂexibility than protein based approaches do, as the latter
require extensive optimization processes for new antigens regarding
production, puriﬁcation and coupling to an anti-DEC-205 antibody [30].
Here, we made use of replication deﬁcient adenoviral vectors [31],
inducing the in vivo production of a fusion protein, consisting of OVA
and a single-chain antibody against DEC-205. Thesewere used to trans-
duce the airwaymucosa, in order to reduce the induction of an asthmat-
ic phenotype in OVA sensitized mice before airway challenge. The
targeting to DCs reduces the required antigen doses [25] and the locally
conﬁned expression might modulate more effectively the immunologi-
cal environment at the mucosal surface. At the same time, the
tolerogenic capacities of prolonged expression in the steady state and
the DEC-targeting in the absence of immunogenic adjuvants are
harnessed. Therefore the here presented work is a promising approach
to ﬁnding a new treatment option for allergic asthma.2. Material and methods
2.1. Adenoviral vectors
Replication deﬁcient adenoviral vectors, encoding for scDEC-OVA,
scGL117-OVA and GFP have been previously described [32]. In short,
the respective expression cassettes were cloned into the pShuttle vector
and used together with the pAdEasy system [33] to produce adenoviral
particles in HEK 293A cells. Antigen expression was conﬁrmed bywest-
ern blot prior to virus puriﬁcation with the Vivapure AdenoPack kit
(Sartorius, Göttingen, Germany). Total particles were determined pho-
tometrically. Infectious particles were determined by the TCID50 meth-
od and the typical ratio of total particles to infectious particles was
approximately 100:1.
2.2. Animals
Female 6–8 week old BALB/cJ mice were purchased from Janvier (Le
Genest-St-Isle, France) and housed in the central animal facility of Ruhr
University Bochum at least for 14 days before experiments to allow for
acclimatization. All mice were housed in accordance with the national
and institutional guidelines.
2.3. Allergen induced asthma model and adenoviral immunization
On days 0 and 14 mice got intraperitoneal injections of 20 μg OVA
(grade V, Sigma, Munich, Germany) and 55 μl Imject Alum (Pierce,
Rockford, IL, USA) in a total volume of 200 μl in sterile ﬁltrated PBS, as
a sensitization against OVA. On days 42 and 52 mice were challenged
for 20 min with an aerosol of 1% OVA in sterile ﬁltrated PBS in order
to induce the asthmatic phenotype. The aerosol was generated with a
PARI TurboBoy SX (PARI, Starnberg, Germany) in a Plexiglas chamber
with a total volume of approximately 11 l. Immunization took place
two weeks after sensitization, on day 28, by intranasal instillation of
109 adenoviral particles in a total volume of 50 μl in sterile PBS. On
day 55 lung functions were measured, BALF was collected by rinsing
lungs twice with 1 ml cold HBSS, and spleens and lungs were excised.
The right lobes of the lungs were used for tissue sections, whereas the
left lobes were used for restimulation experiments. We performed
three independent experiments to demonstrate the therapeutic effect
of the treatment with Ad-Dec-OVA and compared these animals to the
ones from the group Asthma-Control. To further demonstrate the spe-
ciﬁc effect of the DEC205-targeting, we included in one experiment ad-
ditional groups treated either with Ad-GL117-OVA or Ad-GFP. The
numbers of animals per group used for the analyses are listed in Table 1.
2.4. Lung function measurements
Three days after the ﬁnal challenge, mice were anesthetized with
100 mg/kg ketamine and 15 mg/kg xylacine. Spontaneous breathing
was suppressed with 0.8 mg/kg Pancuronium and the airway and lung
tissue reactivity to methacholine was measured using a forced oscilla-
tion technique (FlexiVent, SCIREQ, Montreal, Canada). Using the ‘quick
prime 3’(QP3) perturbation, airway resistance (Rn), tissue damping
(G) and tissue elastance (H) to increasing concentrations of
methacholine (0, 6.125, 12.5, 25 mg/ml) was measured. After each
16 A. Maaske et al. / Journal of Controlled Release 237 (2016) 14–22concentration, the QP3 perturbationwas performed 5 times spread over
2 min. If the Coefﬁcient of Determination of a QP3 perturbation was
lower than 0.90, themeasurement was excluded and not used to calcu-
late the average. For each mouse Rn, G and H were plotted against
methacholine concentration and the area under the curve (AUC) was
calculated to perform statistical analysis.
2.5. Analysis of BAL cells
BALswere centrifuged at 2000×g and the supernatantwas aspirated
and stored at−20 °C. Erythrocytes in the cellular fraction were lysed
using ACK buffer (Lonza, Walkerville, MD, USA). Cell types were subse-
quently analyzed by using either the Diff-Quick kit (Labor und Technik
Eberhardt Lehmann, Berlin, Germany) for differential staining, or by
Flow cytometry. For FACS staining, BAL cells were incubated for
20 min at room temperature in an antibody solution containing anti-
CD45-PerCP-Cy5.5, anti-CD11c-BV450, anti-CD3e-BV510, anti-CD-19-
PE-Cy7 (BD Bioscience), anti-CD49b-PE and anti-Gr-1-AlexaFluor488
(eBioscience). Afterwards cells were washed twice, ﬁxated with 2%
paraformaldehyde solution for 20 min at room temperature and ana-
lyzed with a FACSCanto™ II.
2.6. Antibody titers
ELISA plates were coatedwith 500 ngOVA in 100 μl carbonate buffer
per well at 4 °C overnight. Blocking of free binding sites was performed
with 5% skimmed milk in PBS containing 0.05% Tween-20 (Applichem,
Darmstadt, Germany). Diluted sera or BALF sampleswere added and in-
cubated for 1 h at 4 °C. As detection-antibodies, HRP coupled anti-
mouse IgG1 or IgG2a, or Biotin coupled anti-mouse IgE, followed by
HRP coupled Streptavidin were used (BD Bioscience, Heidelberg, Ger-
many). Plates were developed using in housemade ECL solution and lu-
minescence was measured with a microplate luminometer (Orion L,
Titertek Berthold, Pforzheim, Germany). As an internal standard, pooled
sera from sensitized and challenged mice were used. The content of
OVA-speciﬁc IgG1, IgG2a and IgE in this standard was deﬁned to be
107, 105 and 103 AU/ml respectively. Serial threefold dilutions of this
standard were used to generate a standard curve for each ELISA plate.
2.7. OVA-speciﬁc cytokine production
Left lobes of lungs were cut into pieces of about 3 mm in diameter
and treated with 250 U/ml Collagenase D (Sigma Aldrich, Munich, Ger-
many) and 80 U/ml DNAse I (Applichem) for 45 min at 37 °C. After-
wards, the lung pieces were passed through a 70 μm cell strainer in
order to generate single cell suspensions. Single cell suspensions of
spleens were generated by straining without previous digestion. Cells
were seeded into 48-well plates at either a ﬁxed amount of 5 × 106
cells for spleens, or at a ﬁxed volume for lungs, equivalent to one third
of the total cells. Low endotoxin OVA (hyglos, Bernried, Germany) at a
ﬁnal concentration of 50 μg/ml was used to restimulate cells and 48 h
later supernatants were taken. Ready-SET-Go! ELISA kits (eBioscience,
Vienna, Austria)were used according to themanufacturer's instructions
for measurement of concentrations of IL-4, IL-5, IL-10, IL-13 and IFNγ in
the supernatants.
2.8. Histological sections
Three days after the ﬁnal airway challenge, the right lobes of the
lungs were excised and placed in cold 4% paraformaldehyde solution
for ﬁxation. The samples were embedded in parafﬁn-wax and tissue
sections were generated using a microtome. Hematoxylin and eosin
(HE) staining was used for assessment of inﬂammation and periodic
acid schiff (PAS) staining was used to visualize mucus producing goblet
cells. Stained sections were photographed at a magniﬁcation of 200-
and 400-fold respectively for further analysis. Quantiﬁcation of gobletcell hyperplasia was achieved by calculation of the ratio of PAS positive
cells to PAS negative cells along the basal membrane of bronchioles.
2.9. Statistical analysis
Results are shown as themean± standard error of themean (SEM).
For statistical comparisons GraphPad Prism 5was used (GraphPad Soft-
ware, San Diego, CA, USA) to perform one-way ANOVA or two-way
ANOVA together with Tukey's post test. Results with a p-value ≥0.05
were considered not signiﬁcant. * = p b 0.05, ** = p b 0.01, *** =
p b 0.001, ns = not signiﬁcant.
3. Results
3.1. Speciﬁc reduction of TH2 cytokines without induction of TH1 responses
by DEC-targeted antigen
Sensitization of BALB/c mice by i.p. application of OVA adsorbed to
alum on days 0 and 14, followed by aerosol airway challenges on days
42 and 52 (see Fig. 1A), induces a phenotype resembling themost com-
mon form of human allergen dependent asthma. This includes (but is
not limited to) a TH2 polarization of allergen-speciﬁc CD4+ T-cells, anti-
gen-speciﬁc IgE production, and inﬁltration of the lung by eosinophilic
granulocytes. Intranasal immunizationwith adenoviral vectorswasper-
formed on day 28, inducing the in vivo production of anti-mDEC-205
fused to OVA (Ad-Dec-OVA), anti-β-galactosidase fused to OVA as con-
trol antibody (Ad-GL117-OVA), or GFP as a negative control. Compara-
ble expression levels of OVA fusion proteins as well as robust
immunogenicity have been shown previously [32]. A group of sensi-
tized and challenged, but unimmunizedmicewere used as positive con-
trols for the asthmatic phenotype (Asthma-Control). Three days after
the last allergen-challenge, classic TH2-cytokines in the BAL are already
reverted to or close to background levels, as was already shown by
others [34,35]. Therefore, to investigate whether adenoviral vector im-
munization could inﬂuence the TH2 polarization seen in Asthma-Con-
trol, unsorted single cell suspensions of cells originated from spleen or
lung were restimulated for 48 h with low endotoxin OVA. Induction of
an asthmatic phenotype in Asthma-Control was shown by high
amounts of the classical TH2 cytokines IL-5 and IL-13, as shown in Fig.
1B. Ad-Dec-OVA treated mice showed a signiﬁcant reduction of IL-5
and IL-13 in lung, as well as in spleen, by N50% in comparison to the
Asthma-Control mice. Furthermore, a TH1-shift has not been induced,
as demonstrated by only negligible levels of IFNγ. This also demon-
strates that OVA-speciﬁc CD8+ cells are either not induced or function-
ally inactive. In contrast to Ad-Dec-OVA, neither Ad-GL117-OVAnor Ad-
GFP reduced the amount of TH2 cytokines produced by restimulated
lung cells in comparison to Asthma-Control. Surprisingly, all three ade-
noviral immunizations reduced the amounts of IL-10 produced by
spleen cells. Furthermore, both Ad-GL117-OVA and Ad-GFP have led
to a notable amount of IFNγ, secreted by lung cells. While for Ad-
GL117-OVA, this suggests a slight induction of a TH1 response, Ad-GFP
also increased the amounts of IL-4 in the lung, indicating a generally
pro-inﬂammatory effect. This is in line with a study using a similar ade-
novirus coding for GFP [36].
3.2. DEC-targeting of antigen reduces lung eosinophilia
IL-5 and IL-13 are critical for the recruitment of eosinophils and their
persistence [37,38], therefore we analyzed the effect of our adenoviral
immunization strategies on the cellular composition in the BAL by
ﬂow cytometry, shown in Fig. 2B. In naïve controls, alveolar macro-
phages were by far the predominant cell type, comprising 72.3% of all
cells. In contrast, in Asthma-Control inﬁltration of mainly eosinophilic
granulocytes, as well as a substantial amount of lymphocytes, reduced
the percentage of macrophages to b5% in the BAL. Due to this inﬁltra-
tion, eosinophils amounted to 70.1% of BAL cells in Asthma-Control,
Fig. 1. A Timeline for the induction of the asthmatic phenotype and the adenoviral vector immunization. B Single cell suspensions from lungs or spleenswere stimulatedwith OVA protein
for 48 h and the amounts of indicated cytokines in the supernatant were determined by colorimetric ELISA. Each bar represents the mean concentration and the respective SEM of 5–17
mice according to Table 1. Since IFN-γwas hardly detectable at all; the IFN-γ ElISAwas only performed once and represent 5–6 animals per group. **= p b 0.01, ***= p b 0.001, ns= not
signiﬁcant.
17A. Maaske et al. / Journal of Controlled Release 237 (2016) 14–22while 20.1% of the detected cells were lymphocytes. In comparison, in
Ad-Dec-OVA treated mice, eosinophils were reduced to 38.7%, resulting
in a signiﬁcant increase in the percentage of both lymphocytes andmac-
rophages (38.5% and 15.1% respectively). However, this increase in the
percentage of lymphocytes and macrophages is not accompanied by
an increase in the total numbers. In fact, the total number of lympho-
cytes is not signiﬁcantly different in Ad-Dec-OVA treated mice inFig. 2. FACS analysis of cells in BAL. A BAL was performed three days after the last airway chal
represents the mean percentage among CD45+ cells and the respective SEM of 5–17 mice acc
of the group Asthma-Control could not be properly processed, leaving n= 12 and n= 14 forcomparison with Asthma-Control, but the total number of eosinophils
is reduced by 75% due to the immunization with Ad-Dec-OVA (see Fig.
S1). In line with these numbers, we also observed lower levels of
eotaxin-1, one of the eosinophil chemotactic proteins, in the BAL of
Ad-Dec-OVA treated animals (see Fig. S2). In contrast, immunization
with adenoviral vectors inducing the production of GL117-OVA or GFP
did not lead to signiﬁcant changes in the cellular composition inlenge and the cellular content was analyzed by FACS for the indicated cell types. Each bar
ording to Table 1. Due to technical problems, three samples of the group Naïve and two
these groups. ** = p b 0.01, *** = p b 0.001, ns = not signiﬁcant.
18 A. Maaske et al. / Journal of Controlled Release 237 (2016) 14–22comparison to Asthma-Control. Importantly, the reduced eosinophilia
upon Ad-Dec-OVA treatment did not lead to the induction of airway
neutrophilia.3.3. Reduced antigen-speciﬁc IgE in Ad-Dec-OVA immunized mice
Allergies and asthma are closely related to increased titers in IgE, es-
pecially in the involved tissues [39], which prompted us to analyze the
content of anti-OVA IgE in the BALF by ELISA, shown in Fig. 3. In contrast
to naïvemice, inwhich IgEwas below the detection limit, mice from the
group Asthma-Control showed robust amounts of OVA-speciﬁc IgE in
BALF (for deﬁnition of the arbitrary units, see method section). In com-
parison, the IgE titers in Ad-Dec-OVA treated animals were reduced by
85%, whereas Ad-GL117-OVA and Ad-GFP treated mice showed IgE
levels comparable to the group Asthma-Control. Furthermore, we ana-
lyzed the titers of OVA-speciﬁc IgG1 and IgG2a as an additional assess-
ment for a possible TH1 shift, but no signiﬁcant differences between
OVA sensitized groups were observed. In sera, no effect of adenoviral
immunization on OVA speciﬁc IgG1, IgG2a or IgE was detectable (data
not shown).Fig. 3. OVA-speciﬁc antibodies in BALF. BALs were performed three days after the ﬁnal
challenge and OVA-speciﬁc antibodies were measured by ELISA. The amount of IgE (A),
IgG2a (B) and IgG1 (C) is shown. BD = below detection limit. Each bar represents mean
data and SEM from 5 to 17mice according to Table 1. ***= p b 0.001, ns=not signiﬁcant.3.4. Reduced goblet cell hyperplasia after Ad-Dec-OVA immunization
A common symptom of asthmatic patients is a marked hyperplasia
and activation of mucus producing goblet cells, which correlates with
mortality [40]. Therefore, we analyzed whether the immunological
ameliorations described abovewould translate into a decrease in goblet
cell numbers. Three days after the last airway challenge, the right lobes
of the lungs were excised, ﬁxated in paraformaldehyde and embedded
in parafﬁn. Tissue sections were generated and PAS-stained. In Fig. 4A,
representative micrographs are shown. In naïve mice, PAS positive
cells, representing mucus producing goblet cells, were completely ab-
sent, whereas in mice from the group Asthma-Control, a striking goblet
cell hyperplasia was seen. In contrast, in Ad-Dec-OVA immunizedmice,
only minute amounts of PAS positive cells were observable. Ad-GL117-
OVA treated mice also showed a reduction of goblet cell hyperplasia in
comparison to Asthma-Control, but not as pronounced as seen in the
Ad-Dec-OVA group. Lastly, in Ad-GFP treated mice a change in goblet
cell hyperplasia was hardly noticeable. In order to quantify the reduc-
tion in PASpositive cells,we calculated the ratio of goblet cells to epithe-
lial cells along the basal membrane, shown in Fig. 4B. The group
Asthma-Control showed a mean goblet to epithelial cell ratio of 0.90,
whereas Ad-Dec-OVA mice had a mean of 0.08. Quantiﬁcation of
mRNA for Gob5, a mucus-related gene, from these sections by qRT-
PCR also revealed higher levels for the group Asthma-Control and the
Ad-GL117-OVA in comparison to the mRNA levels in the lung of Ad-
Dec-OVA treated animals (data not shown).
3.5. Ad-Dec-OVA immunization improves lung function
After establishing the ameliorating effect of Ad-Dec-OVA on immu-
nological and histological parameters of the asthma like phenotype,
we wanted to elucidate whether this translates into an improved lung
function. Anesthetized mice were tracheotomized and lung function
was assessed by forced oscillation technique with inhalation of escalat-
ing doses of the bronchoconstrictor methacholine as an aerosol. In Fig.
5A-C, the increase of airway resistance (Rn), tissue damping (G) and tis-
sue elastance (H) in response tomethacholine is shown. All four includ-
ed groups (Naïve, Asthma-Control, Ad-Dec-OVA and Ad-GL117-OVA)
showed a similarly modest increase in Rn. The areas under the curve
(AUC) for RN of the sensitized groups did not differ signiﬁcantly from
the Naïve group. In contrast, for both tissue damping and elastance,
mice from the group Asthma-Control and Ad-GL117-OVA treated mice
showed a signiﬁcantly higher increase than Ad-Dec-OVA mice did
(Fig. 5D-F),whichwas already observable at lowdoses ofmethacholine.
Thus, an overall improved lung function in Ad-Dec-OVA treated mice,
but not mice treated with Ad-GL117-OVA was indeed shown.
4. Discussion
Adenoviral vectors have proven to be efﬁcient for transient immune
manipulations. Their considerable capacity for the transduction of the
airwaymucosa established them as a potent tool for the local induction
of TH1 polarizing agents. Although these approaches were highly efﬁca-
cious as short term treatments in allergic asthma models [14–16], they
lack intrinsic allergen speciﬁcity. Therefore, long term effects would ei-
ther be expected to be absent or would have to stem from unspeciﬁc
reprogramming of the local immune system. As a consequence, TH1 po-
larizing treatments would pose the risk of uncontrolled TH1-based im-
mune reactions towards the allergen [17–19], as well as other
innocuous antigens. In contrast, SIT aims for the induction of speciﬁc tol-
erance, but has a noticably long treatment duration. In the present
study,we utilized adenoviral vectors in order to induce allergen-speciﬁc
tolerance in situ by secretion of a fusion protein, consisting of the aller-
gen and a single-chain antibody against DEC-205. Targeting towards
DCs via DEC-205 not only reduces the required amount of allergen
[41], which is highly beneﬁcial for the safety proﬁle, but also acts
Fig. 4.Histological examination. Three days after the last airway challenge, the right halves of the lungswere excised andﬁxated inparaformaldehyde. Afterﬁxation, lungswere embedded
in parafﬁn wax and sliced using a microtome. Subsequently, slices were stained for histological examination. Magniﬁcation for hematoxylin and eosin (HE) stained samples 200 fold and
for periodic acid Schiff (PAS) 400 fold. A HE (a-e) and PAS (f-j) staining. From left to right: Naïve, Asthma-Control, Ad-Dec-OVA, Ad-GL117-OVA and Ad-GFP. B Ratio of PAS+ goblet cells to
epithelial cells along the basal membrane. Each bar represents the mean of ﬁve sections from each of three mice per group with the respective SEM. * = p b 0.05, ** = p b 0.01, *** =
p b 0.001, ns = not signiﬁcant.
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of this strategy have been successfully used as treatments in murine
models of diabetes [24], contact dermatitis [26] and multiple sclerosis
[42]. Furthermore, in another recent study, a DNA based vaccine,
encoding for a human collagen-domain coupled to anti-DEC-205, re-
duced rejection of human collagen-transgenic skin grafts in mice [43].
We have previously shown that a DNA based systemic immunization
encoding for allergens targeted to DEC-205 has a tolerizing effect. How-
ever, lung resident cells were not sufﬁciently affected in order to treat
an asthmatic phenotype [44] which highlights the importance of the
elicitation of local immune modiﬁcations in the lung mucosa for the
treatment of allergic asthma. Indeed, in the present study, we found
the TH2 inducing cytokine IL-4 to be produced in considerable amounts
only by cells from the lung, but not from the spleen. The same was true
for the production of IFNγ in mice immunized with Ad-GL117-OVA or
Ad-GFP, which are the only groups that showed notable IFNγ produc-
tion at all. This absence of IFNγ production in Ad-Dec-OVA immunized
mice demonstrates the avoidance of TH1 mediated inﬂammation,
which is further supported by the absence of increased OVA-speciﬁc
IgG2a titers. At the same time the risk of type I hypersensitivity reac-
tions, and thus anaphylaxis, is considerably low, taking into account
that OVA-speciﬁc lung IgE titers are reduced by 85% in Ad-Dec-OVA im-
munized mice. Again, this reduction was only observed in the lung,
supporting the hypothesis that local immune modulations are highly
important. It has been shown previously that IgE is produced locally
after allergen challenge in mouse models [45], as well as in human pa-
tients [46]. Nevertheless, said possible tolerance induction is exempli-
ﬁed by the reduction of the TH2 cytokines IL-5 and IL-13 concurrent to
the reduction of IFNγ, in comparison to Ad-GL117-OVA and Ad-GFP.
At least partially as a result of the decrease in IL-5 and IL-13, eosinophilic
granulocytes are reduced in the BAL of Ad-Dec-OVA treated animals, as
IL-5 and IL-13 are crucial for the induction and survival of eosinophils
[37,38,47]. These reduced eosinophile numbers, together with the de-
creased OVA-speciﬁc IgE titers, will consequently lessen subsequent eo-
sinophilic degranulation and thus total inﬂammation in response to
inhalation of the allergen. In accordance with these ﬁndings, goblet
cell hyperplasia and AHR are also reduced in Ad-Dec-OVA treated
mice. The here obtained results for the lung parameters RN, G and H
are in line with a study that used a mouse model that is highly compa-
rable to our Naïve and Asthma-Control groups, in order to compare
forced oscillation technique and alveolar capsules for assessment ofAHR [48]. Furthermore, Riesenfeld et al. noted a time dependent com-
ponent regarding the site of inﬂammation, with increases in RN early
after allergen challenge and a shift towards predominantly increases
in G and H at 48 h after the last allergen challenge [49]. Interesting in
this regard is the occurrence of only minute increases in the resistance
of the conducting airways RN in mice from the group Asthma-Control,
despite the presence of bronchioles that are highly occluded by PAS+
goblet cells in our study. This has general implications for the induced
asthmatic phenotype and indicates a predominantly peripheral and het-
erogeneous inﬂammation, as the effect of occluded distal airways on the
total airway resistance is diminished if parallel conducting airways are
unaffected [50]. Furthermore, increases in lung elastance H and tissue
damping G are in general associated with peripheral inﬂammation
[51]. Tissue distortions or the occurrence of edema for example, can in-
crease H in a widespread area, where compensations as suggested for
RN would not be as easily possible. Moreover, with a uniformly distrib-
uted elastance and heterogeneous resistance of the corresponding
conducting airways, so called “pendelluft” occurs, which signiﬁes the
movement of air back and forth between lung compartments. This
leads to respiratory efforts that do not result in an increased net airﬂow
at the airway opening and would therefore explain at least parts of the
increase in the energy dissipative parameter G, as seen in this study [52].
Based on these considerations, we reason that the asthmatic phenotype
induced by our protocol is characterized by a homogeneous effect on
the tissue compartment and a constriction of the conducting airways
that is heterogeneous as well as restricted to the periphery.
In conclusion, we showed as a proof of principle that mucosally de-
livered viral vectors encoding antigens, fused to a single chain antibody
against DEC-205, are a feasible means to alleviate the symptoms of an
allergic asthma model in an antigen-speciﬁc manner, even after
established sensitization. A single dose vaccination exerted a signiﬁcant
beneﬁcial effect in regard to immunological, histological and lung func-
tion parameters that was not seen with untargeted antigen. Further-
more, we showed that this vaccination scheme reduced the TH2
polarization without the induction of a potentially deleterious TH1 re-
sponse. Together with the observed reduction in allergen-speciﬁc IgE
and in eosinophilic granulocytes, we consider this vaccination to be suf-
ﬁciently safe, although the underlying mechanism should be addressed
in further studies. In regard to the pre-existing immunity to AdV in the
human population, the use of rare serotypes of adenoviruses instead of
AdVmight avoid decreased efﬁcacy due to neutralization of the vaccine
Fig. 5. Effect of immunization with Ad-Dec-OVA on lung function. Three days after the last airway challenge, deeply anesthetizedmice were tracheotomized and connected to a Flexivent
small animal ventilator. Forced oscillationmaneuverswere performedwith orwithout prior inhalation ofmethacholine solutionswith escalating concentrations. A–C inﬂuence of different
doses of methacholine on airway resistance RN (A), tissue damping G (B) and tissue elastanceH (C)D–F corresponding areas under the curve. Each bar represents themean of sixmice per
group with the respective SEM. * = p b 0.05, ** = p b 0.01, ns = not signiﬁcant.
20 A. Maaske et al. / Journal of Controlled Release 237 (2016) 14–22vector. Additionally, other viral vectors which results in constant anti-
gen levels after mucosal delivery, like adeno-associated viruses, might
represent an interesting alternative to analyze in future studies.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.jconrel.2016.06.043.Acknowledgments
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